Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in HRD-Positive Advanced Solid Tumors
NCT06237205Phase 2Not yet recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of niraparib in solid tumor (advanced stage), sponsored by Korea University Anam Hospital. Primary endpoint: Antitumor activity defined as objective response or stable disease at 16 weeks. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06237205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237205.